Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Eli Lilly Chief Corporate Brand Officer Lina Polimeni on how the brand differentiates itself in the crowded pharma market, ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... One concern that co-host David Faber raised during the program was DeepSeek having access to large amounts ...

Over the past six months, Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, it is still a bit surprising, since the ...

We recently compiled a list of the Jim Cramer Discussed These 12 Stocks Amidst The DeepSeek AI Selloff. In this article, we ...

We recently published a list of Jim Cramer’s February Portfolio: Top 10 Stocks. In this article, we are going to take a look ...

Here's why they view Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), and Vertex Pharmaceuticals (NASDAQ: VRTX) as magnificent stocks to buy and hold forever. David Jagielski (Eli Lilly): A ...

Eli Lilly's sales growth is coming short of expectations, which is a problem considering its valuation. The company does have a vast lineup and a deep pipeline that go beyond diabetes and obesity.

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... One concern that co-host David Faber raised during the program was DeepSeek having access to large amounts of data ...

I think Eli Lilly and Company's stock correction may be ending as demand for key drugs Zepbound and Mounjaro remains strong, despite recent sales guidance cuts. The company's high valuation ...

Eli Lilly and Company (NYSE: LLY) will attend the 43rd Annual J.P. Morgan Healthcare Conference, Jan. 13-16, 2025. David A. Ricks, Lilly chair and CEO, will participate in a fireside chat on ...